lose weight

Eisai and Arena Pharmaceuticals are bucking the free sample trend that pharmaceutical companies have followed Reduce Weight Fruta Planta over the last few years. Pharma companies have

slashed their sales team by over 30% from an all-time high of 105,000 seven years ago. In July 2014, ARNA's partner Eisai increased its sales force that is

marketing and detailing the weight loss drug Belviq to 600 reps. ARNA manufactures Belviq like a novel single agent that was authorized by the FDA this year

for weight loss and weight loss.

Distinguishing itself from the two other weight loss drug manufacturers Vivus (NASDAQ:VVUS) and Orexigen (NASDAQ:OREX), on October 15, 2014, ARNA's marketing

partner Eisai implemented free drug samples, that has been another historical hallmark of successful pharmaceutical marketing in decline. Based on Cegedim

Strategic Data, pharmaceutical companies' paying for the free samples that drug representatives bid farewell to in physicians' offices went down more than

25% since 2007. To help keep this successful and necessary marketing tool in perspective, back in the year 2007, pharma companies spent nearly $8.4 billion

on free drug samples, because this would be a great method to introduce and boost sales in a completely new drug. However, recent pharma investment figures

have fallen to approximately $6.3 billion as late as in 2011, due partly to cutbacks in sales representatives by Big Pharma companies.

ARNA's marketing partner Eisai offers free Belviq samples at a time when pharmas are reducing free samples. Clearly, Eisai is executing on its marketing

commitment to ARNA by further penetrating the obesity market with free product samples. According to Cegedim Strategic Data, pharmaceutical paying for

samples given liberated to physicians has declined by 25% since 2007, and also the quantity of sales representatives providing details to physicians in

office visits, including free samples, has additionally significantly came by greater than 35% over the years. This historical chart tracks the correlation

trend between pharma paying for samples and sales rep visits with samples:

According to the chart above, Cegedim Strategic Data estimates the number of drug company detailer visits with free drug samples has dropped even faster,

decreasing 35% from 116 million in 2007 to 76 million this year. Based on Jerry Maynor, director of promoting Cegedim's business development U.S. division,

pharmaceutical companies' "decision to lessen their sales forces is the principal reason sampling has declined". Mr. Maynor also stated, "If we're seeing a

loss of samples at this time, today one of the leading drivers may be the drop in the overall quantity of sales calls being delivered". One of the big

reasons cited for the loss of free samples is pharma sales reps have found it harder than ever to go to physicians, who're pressed for time or find little

value for visits through the reps.

Eisai and ARNA realize that free samples are especially essential for patients trying a brand new weight reduction treatment, since it encourages physicians

and patients to see how effective or well-tolerated it really is. Oftentimes, physicians use prescribing generics like Phentermine, the cheapest weight

reduction drug, for patients who cannot afford a singular top-brand product like Belviq; free Belviq samples should change this dynamic. Meanwhile, Eisai and

ARNA will work on the slow-release formulation for Belviq to ensure that patients do not have to make sure to go ahead and take medicine twice daily, which

can also impact its usefulness.

According to SK&A, approximately 25% of physicians refuse to see pharmaceutical sales reps. In SK&A's 2010 report, laptop computer discovered that nearly

half of physicians will see a sales representative only by appointment, or limit sales detailer visits to times outside patient-care hours, such as before or

after clinics open or during lunch. Other physicians do not have any restrictions on seeing pharmaceutical sales representative. In August 2011, SK&A

reported that 23% of physicians refuse to Super Slim Pomegranate take free samples, but 76% of the physicians surveyed accepted samples, although their probability of doing this

varied by specialty. SK&A figured the bigger practices were less inclined to accept free product samples. Further, 75% of medical practices with 3 to 5

physicians took samples, in contrast to 54% of groups with 10 to 19 doctors.